KRAS and cancer: This mechanistic finding in MPM is consistent with the growing body of evidence that oncogenic RAS/MAPK signaling rewires metabolic pathways to meet the energetic and biosynthetic demands of cancer cells and that ROS is an important metabolic manifestation of KRAS-mediated tumorigenicity [34] and asbestos carcinogenesis in MPM [13–15].